SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: January 13, 2000
BIORA AB
Ideon/Malmo, S-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
X Form 20-F ____ Form 40-F
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
____ Yes X No
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB on
January 13, 2000 announcing several new distribution agreements.
BIORA OPENS THE WAY TO NEW MARKETS
IN ASIA AND SOUTH AMERICA
Malmo, January 13,2000. Biora AB (Nasdaq BIORY) has signed distribution
agreements with well-established distributors in Korea, Taiwan, Puerto Rico
and Colombia. The distributor in Korea is HansMedical Company Ltd, in
Taiwan Taiwan Major Chemical & Pharmaceutical Corp, in Puerto Rico Ophtimed
Instruments and in Colombia Exsal Ltda. The agreement in Colombia also
includes sales and distribution in Venezuela, Ecuador, Peru and Panama.
"Our principal product Emdogain has now achieved broader acceptance and
greater attention in the American market, which was apparent at the yearly
specialist conference in September, based on the attention we received as
well as sales during the conference", said Biora's CEO Tomas Hammargren.
"It is Biora's opinion that a number of dentists and specialists from
countries where we are now beginning to sell our products have attended
these conferences."
"In our judgment, we have made progress in exposing our products to opinion
leaders in each targeted country. We therefore believe that sales can
commence immediately upon receipt of approval from the authorities. In
addition, we have noticed on our home page "biora.com"significant interest
in our products from specialists in the specific countries where we now
plan to start marketing."
Biora develops manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in biology-
based products for specialized dental therapy. Biora's American Depository
Shares are listed on the Nasdaq National Market in the US and Biora's
ordinary shares are listed on the "O-list" of the Stockholm Stock Exchange
in Sweden.
This press release may contain certain forward- looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIORA AB
Dated: January 13, 2000 By: /s/ Anders Agering
--------------------------
Anders Agering
Chief Financial Officer
